Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-T Trial of Glofitamab Induction and Consolidation with CAR-T in r/r LBCL
NCT07542678Phase 2Not yet recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Institut für Klinische Krebsforschung. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07542678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542678.